NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Stevanato Group S.p.A. STVN
7 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€1.2B
▲ 7.4% vs FY2024
EPS · FY25
€0.51
Dividend / sh · FY25
—
Payout · FY25
11%
ROE · FY25
9.7%
Net margin · FY25
11.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 1.2B
Revenue, FY2025 · full 7-year series below
Revenue
Net income
12 cents of every revenue dollar became profit this year.
Per share
EUR 0.51
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
9.7%
Return on equity, FY2025
ROE
Operating margin16.8%
Net margin11.8%
Return on assets5.7%
Each EUR of equity produced 10 cents of profit this year.
Returned to shareholders
EUR 14.7M
returned in FY2025 · dividends + net buybacks
Dividends paidEUR 14.7M
Net buybacks—
Share of profit10.5%
Consecutive raises—
EUR 14.7M in dividends — 11% of the year's profit went back to shareholders.
Growth
+12.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+6.4%
+12.4%
Net income
−0.7%
+12.2%
EPS, diluted
−1.9%
+9.1%
Returned to shareholders
+3.0%
+10.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 2.5B
total assets, end of FY2025
Total assetsEUR 2.5B
EquityEUR 1.5B
CashEUR 130.6M
Gross debtEUR 455.1M
Net debtEUR 324.5M
Current ratio1.76×
Net debt stands at 22% of equity.
History
7 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue €B
1.2
1.1
1.1
1.0
0.8
0.7
0.5
Operating income €B
0.2
0.2
0.2
0.2
0.2
0.1
0.1
EBITDA €B
0.3
0.2
0.3
0.3
0.2
0.2
0.1
Income tax €B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income €B
0.1
0.1
0.1
0.1
0.1
0.1
0.0
EPS, diluted €
0.51
0.43
0.55
0.54
0.53
0.33
0.16
Dividend / sh €
·
·
·
·
·
·
·
Payout %
11
12
10
9
8
11
16
ROE %
9.7
9.3
13.7
15.5
23.3
25.3
·
Shares out B
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed